Nate Lighthizer, OD reviews a study evaluating Acoltremon 0.003% for dry eye disease. In this video, he discusses how the treatment led to an increases in tear volume and tear total lipid concentration with a favorable safety profile, supporting its potential role as a therapeutic option for a broad range of dry eye patients.
